290 related articles for article (PubMed ID: 27017313)
1. Carfilzomib: A cause of drug associated thrombotic microangiopathy.
Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J
Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
[TBL] [Abstract][Full Text] [Related]
3. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
4. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M
BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Camilleri M; Cuadrado M; Phillips E; Wilson W; Jenner R; Pang G; Kamora S; Streetly M; Popat R; Bygrave C; Owen R; Cavenagh J; Chapman M; Sive J; Eccersley L; Sheaff M; Benjamin R; Ramasamy K; Cook G; Virchis A; Chavda SJ; Clifton-Hadley L; Scully MA; Yong K
Br J Haematol; 2021 May; 193(4):750-760. PubMed ID: 33650100
[TBL] [Abstract][Full Text] [Related]
7. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.
Catanese L; Link K; Rupprecht H
BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151
[TBL] [Abstract][Full Text] [Related]
8. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.
Fang W; Sun W; Fang W; Zhao S; Wang C
Int Immunopharmacol; 2024 Jun; 134():112178. PubMed ID: 38728883
[TBL] [Abstract][Full Text] [Related]
9. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
Blasco M; Martínez-Roca A; Rodríguez-Lobato LG; Garcia-Herrera A; Rosiñol L; Castro P; Fernández S; Quintana LF; Cibeira MT; Bladé J; Fernández de Larrea C; Tovar N; Jimenez R; Poch E; Guillen E; Campistol JM; Carreras E; Diaz-Ricart M; Palomo M
Br J Haematol; 2021 Apr; 193(1):181-187. PubMed ID: 32469083
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic microangiopathy after carfilzomib in a very young myeloma patient.
Jeyaraman P; Borah P; Singh A; Chhabra GD; Khullar D; Dayal N; Naithani R
Blood Cells Mol Dis; 2020 Mar; 81():102400. PubMed ID: 31887694
[No Abstract] [Full Text] [Related]
11. Carfilzomib-induced thrombotic microangiopathy. A case report.
Scheggi V; Merilli I; Cesaroni E; Alterini B
J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic microangiopathy during carfilzomib use: case series in Singapore.
Chen Y; Ooi M; Lim SF; Lin A; Lee J; Nagarajan C; Phipps C; Lee YS; Grigoropoulos NF; Lao Z; Surendran S; Teh EM; Goh YT; Chng WJ; Gopalakrishnan SK
Blood Cancer J; 2016 Jul; 6(7):e450. PubMed ID: 27471866
[No Abstract] [Full Text] [Related]
13. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717
[TBL] [Abstract][Full Text] [Related]
14. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.
Maruyama D; Tobinai K; Chou T; Taniwaki M; Shumiya Y; Iida S
Cancer Sci; 2018 Oct; 109(10):3245-3252. PubMed ID: 30058108
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review.
Terao T; Tsushima T; Miura D; Ikeda D; Fukumoto A; Kuzume A; Tabata R; Narita K; Takeuchi M; Matsue K
Leuk Lymphoma; 2022 May; 63(5):1102-1110. PubMed ID: 35373680
[TBL] [Abstract][Full Text] [Related]
16. [Thrombotic microangiopathy with gastrointestinal hemorrhage during carfilzomib therapy for multiple myeloma].
Matsumoto S; Takahashi H; Hamada T; Miura K; Nakagwa M; Kurihara K; Endo T; Koike T; Iizuka K; Iriyama N; Nakayama T; Hatta Y; Nakamura H
Rinsho Ketsueki; 2023; 64(4):255-259. PubMed ID: 37121768
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study.
Kozlowski P; Kameran Behnam K; Uggla B; Åström M
Eur J Haematol; 2020 Jun; 104(6):588-593. PubMed ID: 32115785
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic microangiopathy and indications for therapeutic plasma exchange.
Adamski J
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):444-9. PubMed ID: 25696892
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor associated thrombotic microangiopathy.
Yui JC; Van Keer J; Weiss BM; Waxman AJ; Palmer MB; D'Agati VD; Kastritis E; Dimopoulos MA; Vij R; Bansal D; Dingli D; Nasr SH; Leung N
Am J Hematol; 2016 Sep; 91(9):E348-52. PubMed ID: 27286661
[TBL] [Abstract][Full Text] [Related]
20. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?
Jodele S; Laskin BL; Goebel J; Khoury JC; Pinkard SL; Carey PM; Davies SM
Transfusion; 2013 Mar; 53(3):661-7. PubMed ID: 22804695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
